Multiple Cardiovascular Risk Factors Management According to Guidelines in Patients Initiating Second-Line Glucose-Lowering Treatment in Turkey: Results from the Global DISCOVER Study

Background and Aims: Numerous studies have shown the efficacy of controlling individual cardiovascular risk factors in preventing or slowing atherosclerotic cardiovascular disease in people with diabetes. Furthermore. large benefits are seen when multiple cardiovascular risk factors are addressed si...

Full description

Saved in:
Bibliographic Details
Published in:Turkish journal of endocrinology and metabolism 2018, Vol.22 (2), p.17-18
Main Authors: KÜÇÜKLER, Ferit Kerim, KÜÇÜKARDALI, Yaşar, BAŞPINAR, Osman, ÇALAN, Mehmet, ÇITIRIK, Çağatay, ÇOLAK, Ramis, SARI, Ramazan, ARAZ, Mustafa, TETİKER, Tamer, BAYRAM, Fahri
Format: Article
Language:English
Subjects:
Diabetes
Health risk assessment
Risk factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aims: Numerous studies have shown the efficacy of controlling individual cardiovascular risk factors in preventing or slowing atherosclerotic cardiovascular disease in people with diabetes. Furthermore. large benefits are seen when multiple cardiovascular risk factors are addressed simultaneously. Here. we report glycated haemoglobin (HbA1c). low-density lipoprotein cholesterol (LDL-C). and systolic blood pressure (SBP) management at baseline (initiation of second-line treatment) among Turkish patients participating in the DISCOVER study together with the comparison versus the overall DISCOVER cohort. Materials and Methods: DISCOVER is a 3-year. non-interventional. prospective study assessing treatment and clinical outcomes in patients with T2DM initiating second-line treatment across 37 countries. Consecutive patients with T2DM (aged ≥18 years) were invited to participate in the study if they were scheduled to initiate second-line glucoselowering treatment (add-on or switch) following oral monotherapy. dual therapy or triple therapy in first-line setting. Results: Mean HbA1c. LDL-C and SBP were 8.8%. 131.4 mg/dL and 131.6 mmHg among the Turkish cohort compared to 8.4%. 108.1 mg/dL and 132.3 mmHg in the overall study population. respectively (Table 1). In total. 11.7% of patients had HbA1c
ISSN:1301-2193
1308-9846
DOI:10.25179/tjem.20182202-S51